Leslie A. Fecher
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, COVID-19 and healthcare impacts
Most-Cited Works
- → Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies(2014)5,004 cited
- → Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma(2023)765 cited
- → Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression(2018)596 cited
- → Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial(2012)554 cited
- → Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial(2012)539 cited
- → Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial(2020)513 cited
- → Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor(2012)473 cited
- → Combined MTOR and autophagy inhibition(2014)414 cited
- → Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma(2014)358 cited
- → Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial(2016)332 cited